Beijing Centergate Technologies (Holdings) Co., Ltd. (SHE: 000931) announced that its subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has received a Clinical Trial Approval Notification from China’s National Medical Products Administration (NMPA) for BDB Tablets, a Class 2.3 improved new drug — a novel fixed‑dose combination formulation containing known active ingredients — for the treatment of primary hypertension. The combination has not been marketed in any jurisdiction globally.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval (Notification No. 2026LP02973) |
| Receipt Number | CXHL2600898 |
| Product | BDB Tablets (oral, fixed‑dose combination) |
| Registration Classification | Chemical Drug Class 2.3 (improved new drug — novel combination not marketed domestically or internationally) |
| Indication | Primary hypertension |
| Application Date | 24 July 2026 |
| Approval Date | September 2026 |
| Cumulative R&D Investment | Approximately RMB 5.81 million (~US$0.8 million) as of disclosure date |
Drug Profile & Development Rationale
- Molecule: BDB Tablets, a novel fixed‑dose combination of known active pharmaceutical ingredients for the treatment of primary hypertension. Specific component identities were not disclosed in this announcement.
- Classification Basis: Registered as Class 2.3 under China’s drug registration framework — a category for improved new drugs that combine known active ingredients in a new formulation not previously marketed in China or overseas.
- Clinical Foundation: The individual monotherapy components have demonstrated efficacy and safety in established clinical practice, and their combination use is recommended by clinical treatment guidelines, providing a strong evidence base for the combination approach.
- Therapeutic Rationale: Fixed‑dose combination (FDC) antihypertensive therapies are increasingly favored in clinical practice for their ability to improve medication adherence, simplify dosing regimens, and achieve blood pressure targets more rapidly through complementary mechanisms of action — addressing the well‑documented challenge of therapeutic inertia in hypertension management.
Market Impact & Outlook
- China Hypertension Landscape: China has an estimated ~245 million adults with hypertension, with control rates remaining suboptimal despite widespread availability of generic monotherapies. Fixed‑dose combinations are increasingly adopted in both primary care and specialist settings as guideline‑recommended second‑line therapy when monotherapy is insufficient.
- FDC Differentiation: While numerous antihypertensive FDCs are already marketed in China (e.g., ARB + CCB, ARB + diuretic combinations), BDB’s specific combination — not marketed globally — may offer a differentiated therapeutic profile in terms of efficacy, tolerability, or patient subpopulation targeting. Specific competitive positioning will depend on the undisclosed component identity and clinical trial outcomes.
- Cost‑Efficient Development: With cumulative R&D investment of only ~RMB 5.81 million to date, BDB represents a capital‑efficient development program leveraging well‑characterized active ingredients with established safety profiles — potentially de‑risking the clinical pathway compared to novel molecular entities.
- Regulatory Pathway: As a Class 2.3 drug with known active components, BDB may benefit from abbreviated clinical development requirements relative to Class 1 new drugs, potentially enabling a shorter and less capital‑intensive route to market.
- Portfolio Strategy for Centergate: The clinical trial approval advances Centergate Technologies’ pharmaceutical segment strategy through Shandong Huasu, adding a near‑term hypertension asset to complement its existing product portfolio.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical development plans, and commercial expectations for BDB Tablets. Actual results may differ materially due to risks including clinical trial outcomes, bioequivalence and efficacy data, regulatory review timelines, competitive dynamics in the antihypertensive market, pricing and reimbursement considerations, and the inherent uncertainties of drug development. Investors are advised to exercise caution.-Fineline Info & Tech
